Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S MOTRIN versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S MOTRIN versus NAPROXEN SODIUM.
CHILDREN'S MOTRIN vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
2-4 hours in children; prolonged in neonates and hepatic impairment.
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID